The business of using artificial intelligence to develop medicines is set for a decade of rapid growth. According to a market projection reported by Healthcare Asia Magazine, the global AI-in-pharmaceutical market is expected to reach $28.63 billion by 2034.
The main engine behind that growth, the report says, is drug discovery. Pharmaceutical companies are increasingly leaning on AI to expand and accelerate the earliest stages of developing new treatments — the slow, expensive hunt for promising compounds that has traditionally taken years and consumed enormous budgets.
Geography matters here too. According to the coverage carried by both Healthcare Asia Magazine and MSN, the Asia Pacific region is set to post the fastest growth of any market, signaling that the adoption of AI tools in pharma is far from a purely Western story.
The two source items are closely aligned, both pointing to AI's expanding role across the pharmaceutical industry as the driver of the forecast. Neither goes deep on which specific technologies or companies will capture the largest share, but the direction of travel is clear: AI is moving from a promising experiment to a standard part of how drugs get made.
It's worth remembering that figures like these are forecasts, not guarantees. Market-size projections a decade out depend on assumptions about spending, regulation, and how well the technology actually performs in practice.
Why it matters: if these projections hold, AI could meaningfully change how quickly — and how cheaply — new medicines reach the patients who need them.